OPKO Health to Host Analyst & Investor Day in New York City on June 15

June 14, 2016 4:05pm EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company") announces

that it will host an Analyst & Investor Day on Wednesday, June 15, 2016

beginning at 4:30 p.m. local time in New York City. Phillip Frost, M.D.,

Chairman and Chief Executive Officer of OPKO Health, will host the event

along with other key members of OPKO Health senior management. The

meeting will focus on OPKO Health’s diversified business units and will

provide an update on continued progress in its research and development

and commercial programs. Expert medical leaders in the fields of

prostate cancer, renal disease and endocrinology will be featured

speakers at the meeting.

The presentations and Q&A will be webcast live beginning at 5:00 p.m.

Eastern time. The live and archived webcast will be available on the

Investor Relations section of OPKO Health’s corporate website at www.opko.com .

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes Bio-Reference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore® prostate cancer test and the Claros®1

in-office immunoassay platform. Our pharmaceutical business features

Rayaldee™, a treatment for secondary hyperparathyroidism (SHPT) in stage

3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency

(pending FDA approval) and VARUBI™ for chemotherapy-induced nausea and

vomiting (oral formulation launched by partner Tesaro, IV formulation

(PDUFA January 2017)). Our biologics business includes hGH-CTP, a

once-weekly human growth hormone injection (in Phase 3 and partnered

with Pfizer), and a long-acting Factor VIIa drug for hemophilia

(entering Phase 2a). We also have production and distribution assets

worldwide, multiple strategic investments and an active business

development strategy. More information is available at www.opko.com .

View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006381/en/

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor

Relations

or

Media

Rooney & Associates

Terry

Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

or

Investors

LHA

Anne

Marie Fields, 212-838-3777

or

Bruce

Voss, 310-691-7100

Source: OPKO Health, Inc.

Released June 14, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap